Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the Disease Specific Programme

Babineaux, S.M.; Curtis, Bradley; Holbrook, Tim; Milligan, Gary; Piercy, James

doi:10.1136/bmjopen-2015-010352

Cited by 131 publications

(75 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DSP surveys use validated methods to generate data from clinical practice regarding treatment practices, resource use, and quality of life. 10,11 The Lupus DSP is conducted at regular intervals (previously in 2010 and 2013), and it also collected data from nephrologists and their patients with lupus nephritis; here, we focus on rheumatologists and patients with SLE. The LPP used specific sections of the previous Lupus DSP survey, and both surveys were developed by ARW independent of GlaxoSmithKline (GSK), using the Adelphi Disease Specific Programme method.…”

Section: Methodsmentioning

confidence: 99%

Patient- and Physician-reported Satisfaction With Systemic Lupus Erythematosus Treatment in US Clinical Practice

Pascoe

Lobosco

Bell

et al. 2017

Clinical Therapeutics

View full text Add to dashboard Cite

Purpose: This two-part study comprised two descriptive, cross-sectional surveys to evaluate treatment satisfaction among patients with systemic lupus erythematosus (SLE) and their physicians from US clinical practices. The Lupus Plus Project (LPP; part one) involved belimumab-containing regimens; the Disease Specific Program (DSP; part two) included all treatments and was designed to build on the body of evidence from part one.Methods: The LPP recruited patients receiving belimumab, and comprised 2 paper questionnaires: a patient self-completion questionnaire (PSC) and a patient record form (PRF) completed by the physician. The DSP enrolled patients with SLE receiving any treatment and comprised four parts: a PSC, a PRF completed by the physician after patient consultation, face-to-face physician interviews, and a workload form completed by the physicians to indicate their total SLE patient workload.The key objective of this study was to assess physician and patient satisfaction with current treatment.Findings: From the PSCs, data regarding patientreported satisfaction with current treatment were available for 263 patients who were receiving belimumab combination therapy (LPP) and 250 patients who were receiving non-belimumab treatment (DSP). The majority of patients (belimumab, 86.3% [227/263]; non-belimumab, 78.4% [196/250]) responded positively (at least "somewhat satisfied") when asked about current treatment satisfaction, as did physicians (belimumab, 82.9% [311/375]; non-belimumab, 74.3% [326/439]). In multivariate analysis, factors most strongly associated with

show abstract

Section: Methodsmentioning

confidence: 99%

Patient- and Physician-reported Satisfaction With Systemic Lupus Erythematosus Treatment in US Clinical Practice

Pascoe

Lobosco

Bell

et al. 2017

Clinical Therapeutics

View full text Add to dashboard Cite

show abstract

“…Data used for this analysis are more likely to provide a representative, real-world sample of patients with T2DM and real-world patient behavior than randomized clinical trial data. 10 , 22 For example, in clinical trials, <5% of patients discontinued a GLP1 RA due to GI effects; however, higher rates, between 5% and 10%, have been observed in clinical practice. 23 , 24 Clinical trials have reported the most common AEs with GLP1 RAs to be GI events, including diarrhea, nausea, and vomiting.…”

Section: Discussionmentioning

confidence: 99%

Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes

Sikirica

Martín

Wood

et al. 2017

DMSO

124

101

View full text Add to dashboard Cite

AimNonadherence to glucagon-like peptide-1 receptor agonists (GLP1 RAs) is relatively common among patients with type 2 diabetes mellitus (T2DM). This study sought to identify reasons why patients discontinue GLP1 RAs.Materials and methodsRetrospective data from the Adelphi Diabetes Disease Specific Programme were used. Physicians managing patients with T2DM were surveyed via face-to-face interviews, and patients treated for T2DM were surveyed via self-completed questionnaires. Patient data were stratified by current versus prior GLP1 RA use.ResultsPhysicians (n=443) most frequently reported inadequate blood glucose control (45.6%), nausea/vomiting (43.8%), and gastrointestinal (GI) side effects (36.8%) as reasons for GLP1 RA discontinuation. Patients (n=194) reported the GI-related issues “Made me feel sick” (64.4%) and “Made me throw up” (45.4%) as their top reasons for discontinuation. The most common problems reported (excluding cost) for those currently using GLP1 RAs were “Prefer oral medication over injections” (patients 56%, physicians 32.6%), “Made me feel sick” (patients 38.1%, physicians 16.3%), and “Did not help lose weight” (patients 25.4%, physicians 18%). The most bothersome problems for patients globally (frequency reporting very/extremely bothersome) (excluding cost) were “Difficult to plan meals around” (55.6%), “Made me throw up” (51.6%), and “Caused weight gain” (50%).ConclusionBoth patients and physicians reported GI-related issues as a prominent factor, but disparities between patient experiences and physician perceptions were revealed, suggesting gaps in physician–patient communication. Understanding patients’ expectations of GLP1 RAs and physicians’ patient-management practices may help increase GLP1 RA adherence and thereby potentially enhance diabetes care.

show abstract

“…Data were collected using the Adelphi Prostate Cancer Disease Specific Programme (DSP), an independent, multi-country, cross-sectional survey. Details of the full DSP methodology have previously been described [25], [26], [27]. The Adelphi DSPs do not have any academic or pharmaceutical affiliations.…”

Section: Methodsmentioning

confidence: 99%

A real-world study assessing the use of bone-targeted agents and their impact on bone metastases in patients with prostate cancer treated in clinical practice in Europe

Body

Moos

Rider

et al. 2019

Journal of Bone Oncology

View full text Add to dashboard Cite

BackgroundBone metastases (BMs) are common in patients with prostate cancer and can lead to skeletal-related events (SREs), which are associated with increased pain and reduced quality of life (QoL). Bone-targeted agents (BTAs), such as zoledronic acid and denosumab, reduce the incidence of SREs and delay progression of bone pain.MethodsWe evaluated the management of BMs and pain in six European countries (Belgium, France, Germany, Italy, Spain and the UK) using the Adelphi Prostate Cancer Disease Specific Programme. Patient-reported outcomes (PROs) were used to assess the impact of BMs on pain and QoL.ResultsIn total, 358 physicians completed Patient Record Forms, of whom 246 were oncologists and 112 were urologists. Data were collected on 3667 patients with prostate cancer, including 1971 with BMs and 551 with metastases at sites other than bone (non-BMs). PROs were assessed in 573 patients with BMs and 220 with non-BMs. Most patients with BMs (74%) received a BTA and 53% received treatment within 3 months of BM diagnosis. Patients treated by oncologists were more likely than those treated by urologists to receive a BTA (78% vs. 60%) and to have treatment initiated within 3 months of BM diagnosis (56% vs. 43%). For patients who did not receive a BTA, the main reasons for not treating were very recent BM diagnosis and a perceived low risk of bone complications. Data collected by physicians showed that most patients with BMs (97%) were taking analgesics, with 30% receiving strong opioids. Despite this, 70% were currently experiencing bone pain and 28% were experiencing moderate to severe pain. PRO pain measures showed that 70% of patients with BMs were experiencing moderate to extreme pain, suggesting a disparity between pain levels reported by physicians and by patients.ConclusionsAlthough most patients with BMs receive a BTA, there remain a proportion of patients who are not receiving adequate treatment to prevent SREs or manage pain. Oncologists are more likely to adhere to clinical guidelines than urologists for the prescription of BTAs. Bone pain is common and undertreated. Increasing awareness of SRE prevention and bone pain management might improve patient care.

show abstract

Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the Disease Specific Programme

Cited by 131 publications

References 10 publications

Patient- and Physician-reported Satisfaction With Systemic Lupus Erythematosus Treatment in US Clinical Practice

Patient- and Physician-reported Satisfaction With Systemic Lupus Erythematosus Treatment in US Clinical Practice

Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes

A real-world study assessing the use of bone-targeted agents and their impact on bone metastases in patients with prostate cancer treated in clinical practice in Europe

Contact Info

Product

Resources

About